Marlin Global’s portfolio lagged the broader market in May 2026, weighed down by semiconductor underexposure and near-term revenue challenges in key holdings, while AI-focused stocks powered a narrow rally.
- May gross performance return of -0.7%, adjusted NAV return -1.0%
- Portfolio concentrated in durable AI enablers and platforms like Nvidia and Amazon
- Strong gains from Dexcom (+24%) and Icon (+15%) offset by Zoetis (-32%) and Boston Scientific (-16%)
- Market rally driven by semiconductor surge, with SOXX up 23% in May
- New warrants issued with $0.87 exercise price, expiring April 2027
Portfolio Lags as AI and Semiconductors Dominate
Marlin Global Limited (NZX:MLN) reported a challenging May 2026, with a gross performance return of -0.7% and an adjusted NAV return of -1.0%, underperforming its global benchmark which rose 3.7%. The portfolio’s cautious stance on semiconductors and selective AI exposure contributed to the lag, as the market rally remained remarkably narrow and concentrated in technology and semiconductor stocks.
The SOXX semiconductor index surged 23% in May and is up 90% year-to-date, driven by AI demand. Marlin’s portfolio focuses on AI investments with durable economics, including semiconductor giants ASML, TSMC, Nvidia, and platform leaders Amazon, Alphabet, Meta, and Tencent. These names have lagged the more speculative AI rally but are viewed by the manager as a steadier path to long-term AI participation.
Key Contributors and Detractors Reflect Market Themes
Among the month's top contributors was Dexcom (+24%), which impressed investors with a clearer strategy for expanding continuous glucose monitoring globally; a market still vastly underpenetrated. Icon also gained 15% after an independent audit clarified prior revenue recognition issues and highlighted strong new bookings growth.
On the downside, Zoetis (-32%) faced near-term revenue headwinds from weaker consumer spending and intensified competition in its dermatology segment. Boston Scientific (-16%) flagged slower growth in its Watchman device, attributed to physician and operating room capacity constraints, despite a promising pipeline and long-term growth outlook.
Investment Cycles and Market Sentiment Create Opportunities
Several portfolio holdings, including Tencent (-8%), MercadoLibre (-5%), and Intuitive Surgical (-7%), are navigating investment cycles where current spending weighs on near-term earnings. The market’s focus on immediate profitability has penalised these companies despite evidence that their investments are strengthening competitive moats and driving medium-term growth prospects.
For example, Tencent’s recent launch of AI Agents within its Weixin app sparked a 10% stock rise in early June, underscoring the potential payoff from these strategic initiatives. Marlin’s management sees these valuation gaps as opportunities to back high-quality businesses with durable competitive advantages.
Capital Management and Structural Details
Marlin remains unleveraged with zero gearing and holds a diversified portfolio of 20-35 international growth stocks, predominantly in North America (75%). The portfolio’s sector allocation leans heavily towards Information Technology (26%), Consumer Discretionary (19%), and Health Care (18%).
The company announced a new warrant issue in February 2026, with warrants allotted in April and trading commenced shortly after. The warrants have an exercise price of $0.87 and expire in April 2027, offering shareholders potential capital management flexibility.
Despite the recent underperformance relative to a strong benchmark rally, Marlin’s total shareholder return remains positive over the medium term, supported by a disciplined focus on long-term capital growth and dividends.
Bottom Line?
Marlin’s cautious positioning amid a narrow AI and semiconductor rally highlights valuation tensions and potential opportunities as markets reassess sustainability.
Questions in the middle?
- How will upcoming earnings from key holdings like Icon and Boston Scientific influence Marlin’s near-term performance?
- Can the current AI-driven semiconductor rally sustain its extraordinary profitability levels beyond 2026?
- Will the new warrants issued by Marlin attract shareholder participation or influence liquidity?